New antibody shows promise against Post-Transplant virus threat
NCT ID NCT07261215
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 trial tests a new drug called zuberitamab as a first-line treatment for EBV infection in 20 adults who have had a stem cell transplant. EBV can cause a serious complication after transplant, and current treatments don't work for everyone. Zuberitamab is designed to be more effective at clearing the virus and preventing that complication.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- zuberitamab
- What this could lead to
- If it works, zuberitamab could offer a more effective first-line option to control EBV after transplant, potentially reducing the risk of a life-threatening complication.
- What could go wrong
- This is a small, early-phase trial with only 20 participants, so results may not apply broadly. The drug may not work better than existing treatments, and side effects are still being studied.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EBV INFECTION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new drug combo reset the immune system to beat relapsed leukemia?
- Immune cells engineered to hunt viruses show promise for transplant kids
- Supercharged immune cells take on Drug-Resistant infections
- Donor cells take on Drug-Resistant viruses in new trial
- New study aims to predict hidden hepatitis b danger in transplant patients
- New drug gecacitinib tested for tough transplant complication